<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657186</url>
  </required_header>
  <id_info>
    <org_study_id>TAR/006118</org_study_id>
    <nct_id>NCT03657186</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects</brief_title>
  <official_title>Double-blind, Randomised, Placebo-controlled Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TargEDys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Analyze &amp; Realize</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TargEDys</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effects of ProbioSatys™ on body weight and related parameters&#xD;
      in overweight subjects during a 12-week consumption period. In addition, tolerability and&#xD;
      safety of ProbioSatys™ will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ProbioSatys™ is a probiotic nutritional solution containing a commensal Enterobacteriaceae&#xD;
      food grade strain, Hafnia alvei 4597. The microbiome is known to play a crucial role in body&#xD;
      weight management and metabolic disease. ProbioSatys™ mechanism of action relies on bacterial&#xD;
      metabolites that send local and central signals via the gut-brain axis by molecularly&#xD;
      mimicking satiety hormones involved in appetite regulation.&#xD;
&#xD;
      Numerous ProbioSatys™pre-clinical studies indicate that consumption of the strain leads to&#xD;
      body weight loss based on food intake reduction, but also improvement of body composition&#xD;
      (increase of lean mass/fat mass ratio), and improvement of glucose metabolism (oral glucose&#xD;
      tolerance test, and fasted glycemia).&#xD;
&#xD;
      The present study aims to evaluate the effects of ProbioSatys™ on body weight and related&#xD;
      parameters in overweight subjects during a 12-week consumption period. In addition,&#xD;
      tolerability and safety of ProbioSatys™ will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Actual">November 28, 2019</completion_date>
  <primary_completion_date type="Actual">November 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who lost at least 3% of baseline body weight (=&quot;3% responders&quot;)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight change (in kg), compared to baseline (V2)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight change (%), compared to baseline (V2)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (in kg )</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost at least 3% of baseline body weight (=&quot;3% responders&quot;)</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost at least 5% of baseline body weight (=&quot;5% responders&quot;)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat mass assessed per bioelectrical impedance analysis (BIA), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat free mass assessed per bioelectrical impedance analysis (BIA), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism parameters (total cholesterol), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism parameters (high density lipid cholesterol), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism parameters (low density lipid cholesterol), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated haemoglobin (HbA1c), compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the overall feeling of satiety compared to baseline by using visual analogue scales (VAS)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>continuous line between two endpoints: not saturated at all &amp; fully saturated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the overall feeling of fullness compared to baseline by using visual analogue scales (VAS)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>continuous line between two endpoints: not full at all &amp; extremely full</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the overall feeling of craving compared to baseline by using a 5 point Likert scale</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>0= &quot;no&quot;, 1= &quot;slightly&quot;, 2= &quot;moderate&quot;, 3= &quot;strong&quot; and 4= &quot;very strong&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General well-being parameters (Impact of Weight on Quality of Life-Lite, IWQOL-LITE), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of benefit at V5 by subject and the investigator</measure>
    <time_frame>12 weeks</time_frame>
    <description>&quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of adverse events throughout the study</measure>
    <time_frame>14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulse rate, compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (haemoglobin)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (haematocrit)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (thrombocytes)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>analysis of full blood count parameters (leucocytes)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (alanine transaminase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (aspartate aminotransferase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (gamma-glutamyltransferase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (alkaline phosphatase)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (bilirubin)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (creatinine)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (urea)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety laboratory parameters, compared to screening values (V1)</measure>
    <time_frame>14 weeks</time_frame>
    <description>liver and renal function parameters (uric acid)</description>
  </other_outcome>
  <other_outcome>
    <measure>Global evaluation of tolerability at V5 by subject and the investigator</measure>
    <time_frame>12 weeks</time_frame>
    <description>&quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal tolerability parameters (Gastrointestinal Symptom Rating Scale questionnaire, GSRS), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency in the week before each visit post- baseline, each compared to the week before baseline (V2)</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity parameters (Global Physical Activity Questionnaire, GPAQ), compared to baseline</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Overweight</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>ProbioSatys™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ProbioSatys™</intervention_name>
    <description>One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.</description>
    <arm_group_label>ProbioSatys™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 65 years old males and females&#xD;
&#xD;
          2. Overweight (Body Mass Index, BMI: 25 kg/m2 - 29.9 kg/m2)&#xD;
&#xD;
          3. Generally in good health&#xD;
&#xD;
          4. Desire to lose weight&#xD;
&#xD;
          5. Regularly consuming 3 main meals/day (breakfast, lunch, dinner)&#xD;
&#xD;
          6. Readiness to comply with study procedures, in particular:&#xD;
&#xD;
               -  Follow diet recommendation&#xD;
&#xD;
               -  Maintain the habitual level of physical activity during the study&#xD;
&#xD;
               -  Fill out the questionnaires and subject diary&#xD;
&#xD;
               -  Take the IP as instructed&#xD;
&#xD;
          7. Stable body weight in the last 3 months prior to V1 (≤5% self-reported change)&#xD;
&#xD;
          8. Stable concomitant medications (if any) for at least last 3 months prior to V1&#xD;
&#xD;
          9. Women of childbearing potential:&#xD;
&#xD;
               -  Negative pregnancy testing (beta HCG-test in urine) at V1&#xD;
&#xD;
               -  Women of childbearing potential: commitment to use contraception methods (with&#xD;
                  the exception of starting new contraception medication)&#xD;
&#xD;
        Participation is based upon written informed consent form by the participant following&#xD;
        written and oral information by the investigator regarding nature, purpose, consequences&#xD;
        and possible risks of the clinical study.&#xD;
&#xD;
        Randomisation criteria (to be checked after run-in at V2):&#xD;
&#xD;
          1. No change in body weight or reduction up to 3 kg (compared to V1)&#xD;
&#xD;
          2. Adequately completed subject diary&#xD;
&#xD;
          3. Readiness and ability to comply with study requirements&#xD;
&#xD;
          4. Relevant inclusion and exclusion criteria met&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy/sensitivity to any components of the investigational product&#xD;
&#xD;
          2. Pathological electrocardiogram (ECG) at V1&#xD;
&#xD;
          3. History and/or presence of clinically significant self-reported disorder as per&#xD;
             investigator's judgement:&#xD;
&#xD;
               -  Untreated or non-stabilised thyroid gland disorder&#xD;
&#xD;
               -  Untreated or non-stabilised hypertension (regular systolic blood pressure ≥ 140&#xD;
                  mmHg and/or diastolic blood pressure ≥ 90 mmHg)&#xD;
&#xD;
               -  Digestion/absorption disorders of the gastrointestinal tract (e.g. inflammatory&#xD;
                  bowel disease, coeliac disease, pancreatitis etc.) and/ or gastrointestinal&#xD;
                  surgery&#xD;
&#xD;
               -  Diabetes mellitus type 1 or untreated/non-stabilised type 2&#xD;
&#xD;
               -  Acute or chronic psychotic disorder&#xD;
&#xD;
               -  Immunodeficiency&#xD;
&#xD;
               -  Any other organ or systemic diseases that could influence the conduct and/or&#xD;
                  outcome of the study and/or could affect the tolerability of the subject&#xD;
&#xD;
          4. History and/or presence of eating disorders like bulimia, anorexia nervosa,&#xD;
             binge-eating as per investigator's judgement&#xD;
&#xD;
          5. Any electronic medical implant&#xD;
&#xD;
          6. Deviation of safety laboratory parameter(s) at V1 that is:&#xD;
&#xD;
               -  Clinically significant or&#xD;
&#xD;
               -  &gt;2x upper limit of normal, unless the deviation is justified by a previously&#xD;
                  known not clinically relevant condition (e.g. Gilbert's syndrome)&#xD;
&#xD;
          7. Use of medication/supplementation in the last month prior to V1 and during the study,&#xD;
             as per investigator's judgement:&#xD;
&#xD;
               -  That could influence gastrointestinal functions (such as antibiotics, probiotics,&#xD;
                  laxatives, opioids, anticholinergics, anti-diarrheals etc.)&#xD;
&#xD;
               -  For weight management (e.g. fat binder/burner, satiety products etc.)&#xD;
&#xD;
               -  That could influence body weight (e.g. antidepressants, systemic corticoids etc.)&#xD;
&#xD;
               -  That could otherwise interfere with study conduct / evaluation&#xD;
&#xD;
          8. Diet/weight loss programs within the last 3 months prior to V1 and during the study&#xD;
&#xD;
          9. Smoking cessation/modification of smoking level (if any) within 6 months prior to V1&#xD;
             and/or during the study (regular smoking during the study at the same level as prior&#xD;
             to the study is allowed)&#xD;
&#xD;
         10. Vegetarian, vegan or other restrictive diet&#xD;
&#xD;
         11. Pregnancy or nursing&#xD;
&#xD;
         12. History of or current abuse of drugs, alcohol or medication&#xD;
&#xD;
         13. Inability to comply with study procedures&#xD;
&#xD;
         14. Participation in another study during the last 30 days prior to V1&#xD;
&#xD;
         15. Any other reason deemed suitable for exclusion, per investigator's judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Analyze &amp; Realize</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Grube</name>
      <address>
        <city>Berlin</city>
        <zip>10709</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jörg Förstermann</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Hafnia alvei</keyword>
  <keyword>Overweight</keyword>
  <keyword>Food intake</keyword>
  <keyword>Appetite regulation</keyword>
  <keyword>Satiety</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Glucose Metabolism</keyword>
  <keyword>Glycemia</keyword>
  <keyword>Enterobacteriaceae</keyword>
  <keyword>Gut-brain axis</keyword>
  <keyword>Molecular mimicry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

